Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2005

View Archived Issues

PET studies predict a very low abuse liability of a new antidepressant

In vivo evidence that PARP inhibitors reduce cardiac dysfunction during transplantation

Modulation of astrocytic function as an alternative approach for the treatment of schizophrenia

Interleukin-4 mediates inflammatory modulation of synaptic function in the hippocampus

TA-375 and TA-380 tested on stunned myocardium in dogs

Lorus Therapeutics signs collaboration agreement with Sumitomo and Koken

NIAID to test Tarvacin for antiviral potential

Yakult launches Elprat for colorectal cancer in Japan

Phase I/II study evaluates Inovio's DNA delivery technology in prostate cancer

Clickhaler asthma products receive approvals in European market

New patents describe therapeutic agents for psychiatric disorders

Novel monoclonal antibodies imparted by Biogen Idec for use in immunosuppression

A phase III study supports the use of rituximab in rheumatoid arthritis

Promising phase II results reported for belimumab in rheumatoid arthritis

Neuroprotective efficacy of repinotan hydrochloride, a 5-HT1A receptor agonist / News in Context

Transdermal methylphenidate shows efficacy in children with ADHD

Serono discontinues two phase III programs

INCB-7839 enters phase I trial

IND clearance allows phase I study of ZIO-101 in hematological cancers

GCS-100LE studied in phase I/II study for multiple myeloma

ImaRx studies Sonolysis in phase II stroke study

Argos' personalized melanoma vaccine studied in Germany

Phase II breast cancer study of KOS-862 to proceed

Enrollment completed in phase III study of Trisenox consolidation in APL

Siplizumab under investigation for CD2-positive lymphoproliferative disorders

Schwarz Pharma's rotigotine NDA accepted for filing

Celebrex gets boxed warning; Bextra suspended

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...